Surmodics Introduces the Pounce XL Thrombectomy System
Surmodics, Inc. (NASDAQ: SRDX), based in Eden Prairie, Minnesota, has made significant strides in the medical device arena with the introduction of its Pounce™ XL Thrombectomy System. This innovative system is specially designed for the non-surgical removal of thrombi and emboli from iliac and femoral arteries, which are critical for restoring adequate blood flow.
FDA Clearance and Market Release
The Pounce XL Thrombectomy System received its 510(k) clearance from the U.S. Food and Drug Administration (FDA), a vital step in ensuring its marketplace acceptance. As it stands, the system is in limited market release, and a full commercial launch is anticipated once this phase is complete. This product stands to enhance treatment protocols in vascular surgery, allowing healthcare professionals to perform procedures more effectively.
Clinical Success Stories
Dr. Walter Rizzoni, a vascular surgeon affiliated with the University of Pittsburgh Medical Center (UPMC) Hamot, was among the first to utilize the Pounce XL system. During a recent procedure in Erie, Pennsylvania, he successfully restored blood flow in a thrombosed stent graft, utilizing the device on an 8 mm diameter stent. His positive experience and the performance of the device underline its potential in clinical settings.
Dr. Rizzoni stated, “The Pounce XL Thrombectomy System removed a significant amount of chronic material during our first use. Its performance was right in line with our experience using the original Pounce and Pounce LP Systems.” This feedback not only highlights the effectiveness of the system but also reinforces its positioning in the market as a highly valuable tool for healthcare practitioners.
Overview of the Pounce Thrombectomy Platform
The Pounce Thrombectomy Platform consists of three devices, each uniquely suited for removing organized thrombus or embolus from arteries of varying sizes. Specifically, it includes the Pounce Thrombectomy System for 3.5–6 mm vessels, the Pounce LP (Low-Profile) System for 2–4 mm vessels, and the newly introduced Pounce XL for larger vessels ranging from 5.5–10 mm in diameter.
What sets these systems apart is their fully mechanical operation, enabling swift removal without the use of thrombolytics or large aspirational equipment. This innovation is particularly beneficial for swift interventions that can significantly impact patient recovery and hospital stay duration.
Innovative Design and Functionality
The Pounce XL Thrombectomy System is indeed a cutting-edge solution—characterized by its “grab-and-go” functionality. It features a straightforward design with three main components: a delivery catheter, a basket wire, and a funnel catheter. The design allows for easy deployment and retrieval of clots, simplifying the thrombectomy procedure while minimizing patient discomfort.
The process involves delivering the basket wire to the clot site through the delivery catheter, deploying expandable nitinol baskets that trap the clot for safe removal. This efficient technique promises reduced invasiveness while maintaining effectiveness.
Insights from the PROWL Registry
Among the ongoing assessments of the Pounce Thrombectomy Platform is the PROWL registry, which is focused on the non-surgical treatment of peripheral artery emboli and thrombi. Early data has shown promising results, including a high rate of procedural flow restoration among subjects with symptoms of limb ischemia.
At a recent medical conference, promising results were presented detailing a substantial percentage of patients not requiring additional thromboemboli treatments after using the Pounce systems. These findings could be instrumental in redefining treatment paths for patients suffering from peripheral artery diseases.
About Surmodics, Inc.
Surmodics, Inc. is recognized for its forward-looking initiatives in developing advanced medical technologies. The company specializes in performance coating technologies aimed at enhancing intravascular medical devices, along with a range of diagnostic tools that bolster healthcare solutions. Surmodics remains committed to addressing unmet clinical challenges through innovation and excellence in product development.
Frequently Asked Questions
What is the Pounce XL Thrombectomy System?
The Pounce XL Thrombectomy System is a medical device designed for the non-surgical removal of thrombi and emboli specifically in the iliac and femoral arteries.
What size vessels is the Pounce XL intended for?
The Pounce XL Thrombectomy System is indicated for vessels ranging from 5.5 to 10 mm in diameter.
How does the system work?
The system works by deploying expandable baskets that capture and remove clots without the need for thrombolytics or large equipment.
Who is involved in the clinical use of the device?
Surgeons like Dr. Walter Rizzoni have successfully used the Pounce XL in clinical settings to restore blood flow in patients.
Where is Surmodics, Inc. headquartered?
Surmodics, Inc. is headquartered in Eden Prairie, Minnesota, where it conducts its research and development efforts.
